Patients with amyotrophic lateral sclerosis are willing to tolerate a lot more risk than other stakeholders have assumed, advocates argued during a day-long public hearing Feb. 25 where they offered their advice on such topics as the design of clinical trials and access to experimental therapies to treat the aggressive and always-fatal neurodegenerative disease.
The meeting was part of the agency’s move to adopt a more patient-focused view toward drug development. A series of meetings mandated under the reauthorization of the Prescription Drug User...